About Gene Solutions
Gene Solutions is a pioneering and prominent genetic testing company in Asia dedicated to developing and providing access to next-generation genetic testing. The company delivers on:
- Reproductive Health: Offering unique Non-invasive Prenatal Testing (NIPT) that integrates screening for recessive and dominant single-gene disorders.
- Clinical Oncology: Including multi-cancer early detection (MCED), comprehensive genomic profiling (CGP) for precision therapy selection, and minimal residual disease (MRD) tracking using circulating tumor DNA (ctDNA) technology.
Gene Solutions envisions elevating healthcare in the region through advanced genomics and multi-dimensional artificial intelligence. With over 2.2 million tests provided to patients, the company demonstrates its commitment to accessible genetic testing services.
Eight Years of Research and Clinical Trials conducted By Dedicated Molecular Biologists, Bioinformaticians and Medical Oncologists
Publications
Over 40 peer-reviewed publications, with more than 20 focused on oncology in top journals like Nature Scientific Reports, eLife Sciences, BioMed Central, Frontiers in Oncology, and ESMO publications.
Awards & Presentations
18 award-winning abstracts and oral presentations at prestigious international oncology conferences, including the ASCO Annual Meeting, ASCO Breakthrough, and ESMO Asia.
Pioneering applications of ctDNA transforming personalized cancer care
High-sensitivity assays interpreted with AI-powered analytics to identify circulating tumor DNA (ctDNA) in the bloodstream.
Early cancer
detection by ctDNA
The SPOT-MAS test utilizes next-generation sequencing (NGS) and artificial intelligence (AI) to analyze multiple characteristics of circulating tumor DNA (ctDNA) from blood. This advanced approach enables the early detection of the most common and aggressive cancers.
- 99.8% Specificity *
- 99.9% Negative Predictive Value (NPV)
- 78.1% Sensitivity
- 84% Tumor location prediction (TOO) accuracy
* The performance of SPOT-MAS has been proven in multiple studies and a clinical validation involving 9,024 participants: Le Son Tran et al. Analytical and clinical validation of a circulating tumor DNA-based assay for multicancer early detection.. JCO 42, 10548-10548(2024).DOI:10.1200/JCO.2024.42.16_suppl.10548
Visit product website at: www.spotmas.comGenomic Profiling and Personalized Cancer Monitoring
- Comprehensive Genomic Profiling (155-473 gene-panels): Actionable/resistant mutations, Germline mutations, Microsatellite Instability (MSI), with option for PD-L1 & Tumor Mutational Burden (TMB).
- Personalized ctDNA profiling for Minimal Residual Disease (MRD) detection, recurrence prognosis, relapse tracking and treatment response monitoring.
- Pan-cancer analysis in both early or metastatic stages.
